Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK.

MLA

Stirnadel-Farrant, Heide A., et al. “Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid Use Among Adults with Systemic Lupus Erythematosus in the UK.” Rheumatology & Therapy, vol. 10, no. 5, Oct. 2023, pp. 1167–82. EBSCOhost, https://doi.org/10.1007/s40744-023-00566-w.

APA

Stirnadel-Farrant, H. A., Golam, S. M., Naisbett-Groet, B., Gibson, D., Langham, J., Langham, S., & Samnaliev, M. (2023). Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK. Rheumatology & Therapy, 10(5), 1167–1182. https://doi.org/10.1007/s40744-023-00566-w

Chicago

Stirnadel-Farrant, Heide A., Sarowar M. Golam, Barbara Naisbett-Groet, Danny Gibson, Julia Langham, Sue Langham, and Mihail Samnaliev. 2023. “Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid Use Among Adults with Systemic Lupus Erythematosus in the UK.” Rheumatology & Therapy 10 (5): 1167–82. doi:10.1007/s40744-023-00566-w.